뒤로
BeOne Medicines AG(6160.HK) 가격
6160.HK 주가 차트
BEONE MEDICINES (6160.HK)
BeOne Medicines AG
HK$198.1
-0.95%
$-1.9
정규장: Jan 20, 15:06:19 HKT
A
최종 점수
주요 통계
이전 종가
$200.4
시가
$200
일일 범위
$197 - $200.4
52주 범위
$115.8 - $229.4
거래량
1.0M
평균 거래량
3.9M
EPS(TTM)
0.31
배당수익률
--
시가총액
$262.1B
BEONE MEDICINES란 무엇인가요?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.